This article was originally published in The Rose Sheet
Executive SummaryCompany has received all of the required lender consents to increase its existing $700 mil. term loan facility by $100 mil. under an amendment to its bank credit agreement dated 2004, Revlon announces July 24. Firm expects to close and fund the amendment July 28, "subject to market and other customary conditions," firm notes. Revlon announced it was seeking an amendment to the credit agreement earlier this month (1"The Rose Sheet" June 26, 2006, In Brief)...
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 10)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this tenth and final installment of a 10-part series, the experts explain why it’s important to be honest with investigators at all times.